NovaBridge Biosciences (NBP) Income from Continuing Operations (2019 - 2025)
NovaBridge Biosciences (NBP) reported Income from Continuing Operations of 72858000.0 for Q4 2025, down 571.87% year-over-year from 15440143.68 in Q4 2024, and down 967.05% quarter-over-quarter from 6828000.0 in Q3 2025.
NovaBridge Biosciences (NBP) Income from Continuing Operations (2019 - 2025) Analysis & Trends
NovaBridge Biosciences (NBP) has 5 years of Income from Continuing Operations data on file, last reported at 72858000.0 in Q4 2025.
- Income from Continuing Operations for Q4 2025 came in at 72858000.0, down 571.87% year-over-year; the trailing twelve-month figure through Dec 2025 was 88340000.0 (down 77.76% YoY), and the FY2025 annual result was 88340000.0, down 77.76% from the prior year.
- Income from Continuing Operations eased to 72858000.0 in Q4 2025 per NBP's latest filing, from 6828000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 3150000.0 in Q1 2025 and troughed at 72858000.0 in Q4 2025.
- A 3-year average of 19156818.18 and a median of 9419000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations jumped 70.62% in 2024, then slumped 571.87% in 2025.
- A 3-year view of Income from Continuing Operations shows it stood at 36910000.0 in 2023, then jumped by 70.62% to 10844000.0 in 2024, then tumbled by 571.87% to 72858000.0 in 2025.
- Business Quant data shows NBP's Income from Continuing Operations at 72858000.0 in Q4 2025, 6828000.0 in Q3 2025, and 5504000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | NovaBridge Biosciences | 328.19 Mn | 117.34 Mn | - | -72.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -72.86 Mn |
| Sep 30, 2025 | -6.83 Mn |
| Jun 30, 2025 | -5.50 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Dec 31, 2024 | -10.84 Mn |
| Sep 30, 2024 | -20.49 Mn |
| Jun 30, 2024 | -8.94 Mn |
| Mar 31, 2024 | -9.42 Mn |
| Dec 31, 2023 | -36.91 Mn |
| Sep 30, 2023 | -8.22 Mn |
| Jun 30, 2023 | -27.56 Mn |
| Dec 31, 2020 | 160.85 Mn |
| Sep 30, 2020 | -82.36 Mn |
| Dec 31, 2019 | -49.46 Mn |
| Sep 30, 2019 | -35.10 Mn |